Mounjaro Titration: How the Dose Escalation Schedule Works

What the trial data established about dose and weight loss

The SURMOUNT-1 study, published in the New England Journal of Medicine, randomised 2,539 adults with obesity across three tirzepatide doses and a placebo arm over 72 weeks. The findings showed a clear dose-response relationship: participants on 5 mg lost an average of around 15 % of body weight, those on 10 mg around 19 %, and those on 15 mg around 20–21 %. That gradient matters clinically. It tells prescribers that the upper doses are where the greatest benefit tends to emerge, which is why the titration schedule is designed to work up toward them rather than to stay at a fixed lower dose indefinitely.

The trial also revealed something practical for anyone starting treatment: significant weight loss continued accumulating well past the first few months. People who reached the maintenance dose and stayed there kept losing weight through to week 72. That long arc is partly why the titration schedule is unhurried by design. Rushing through dose steps to reach 15 mg quickly does not produce faster results; the body needs time to adjust at each level before the prescriber can judge whether to move on. For a more detailed look at how each individual strength fits into the broader schedule, the Mounjaro titration schedule page breaks down the timing at every step.

How the titration steps work in practice

The licensed UK schedule begins at 2.5 mg for a minimum of four weeks. The first pen's purpose is purely to acclimatise your gut to tirzepatide. Nausea, burping and changes in appetite are most noticeable here, and they usually ease before the four weeks are up. After that initial period, your prescriber reviews your progress and, if appropriate, moves you to the 5 mg injection, which is the first active treatment dose in the schedule.

From 5 mg onward, each step follows roughly the same four-week minimum, though a prescriber may extend any step if side effects are still settling or if your weight loss at the current dose is meaningful enough to warrant staying put. The decision to stay at 5 mg is more common than people expect; it is a valid clinical choice, not a failure. The BNF entry for tirzepatide confirms this graduated approach, noting that the dose is increased in 2.5 mg increments at intervals of at least four weeks based on tolerability. When tolerability is established and progress reviewed, your prescriber may move you to the 10 mg injection, which represents the midpoint of the full titration range. The 12.5 mg and 15 mg steps follow the same logic: minimum four weeks, clinical review, then a decision.

One practical note: a 5 mg pen, a 10 mg pen or any other strength in the schedule arrives as a single KwikPen containing four doses, one per week for the month. If you order through a regulated online pharmacy, your pen comes in plain, unbranded packaging via tracked DPD next-working-day delivery, so there is nothing to signal what is inside. What is inside is the product dispensed by a GPhC-registered pharmacy against your prescription.

Why dose increases are never automatic or guaranteed

A common misunderstanding is that titration is a conveyor belt: four weeks pass, next dose arrives. It is not. Every repeat supply and every dose change at nume is clinically re-reviewed before dispatch, a real prescriber reads your update, not an algorithm processing your payment. That review considers whether you experienced any side effects that need addressing, whether your weight has moved as expected, and whether anything in your health picture has changed.

The NICE technology appraisal for tirzepatide (TA1026) also includes a clinical stopping rule: if you have not lost at least 5 % of your body weight after six months at your highest tolerated dose, continuing treatment should be reviewed. This is not a punishment clause, it reflects the reality that tirzepatide does not produce the same response in every person, and prescribers need the latitude to reassess. The titration schedule is therefore always a clinical conversation, not a fixed programme you run independently. Questions about whether to increase, pause or stop belong with your prescriber, never in a forum. If you are unsure how your current dose is working, the support team can connect you with your prescriber the same day.

Side effects during titration and what to watch for

Most of the unwanted effects associated with Mounjaro cluster around transitions, starting treatment or moving up a step. Nausea is the most frequently reported, followed by loose stools or constipation, reflux and fatigue. For most people these are mild and settle within the first week or two at each new dose. The NHS patient information for tirzepatide, available at nhs.uk/medicines/tirzepatide, lists the common and uncommon effects with clear guidance on when to contact a doctor.

Serious but rarer effects deserve explicit mention. Severe, persistent stomach pain that radiates to the back (with or without vomiting) warrants urgent medical attention, as this can be a sign of pancreatitis. Symptoms suggesting an allergic reaction, gallbladder problems or significant dehydration from prolonged vomiting also need prompt review. These are not reasons to avoid treatment; they are reasons to stay in contact with a prescriber throughout titration rather than managing it alone. Tirzepatide dose titration is safest when there is clinical oversight at every step, which is what repeat review at a regulated pharmacy is designed to provide. When the time comes to reduce or stop treatment, our guide on how to titrate off tirzepatide safely covers the steps your prescriber is likely to recommend. If you would like to understand the full context of private treatment, including what it costs, the Mounjaro prices page sets out what is included in a single transparent fee.

If you are wondering whether tirzepatide is appropriate for your situation, checking your eligibility through a free consultation is the right starting point. A GPhC-registered prescriber reviews your answers the same day.